Saffroy, Raphael, Morère, Jean-François, Bosselut, Nelly, Innominato, Pasquale F., Hamelin, Jocelyne, Trédaniel, Jean, Masse, Sophie, Dussaule-Duchatelle, Véronique, Balaton, André, Validire, Pierre, Guettier, Catherine, Bouchahda, Mohamed and Lemoine, Antoinette (2017) Impact of country of birth on genetic testing of metastatic lung adenocarcinomas in France : African women exhibit a mutational spectrum more similar to Asians than to Caucasians. Oncotarget, 8 . pp. 50792-50803. doi:10.18632/oncotarget.15132 ISSN 1949-2553.
Preview |
PDF
WRAP-impact-country-birth-genetic-Innominato-2017.pdf - Published Version - Requires a PDF viewer. Available under License Creative Commons Attribution . Download (2MB) | Preview |
Abstract
Background: Limited data are available on the prevalence of oncogenic driver mutations in Caucasian populations, and especially in Europeans.
Aim: To evaluate the targetable mutational spectra in unselected patients with lung adenocarcinoma in routine clinical practice from several French hospitals, using the same molecular platform.
Patients and Methods: Samples from 2,219 consecutive patients with histologically-proven advanced lung adenocarcinoma were centrally analysed at a referenced and certified diagnostic platform in order to test for activating and resistance mutations in EGFR, KRAS, BRAF, ERBB2 and PI3KCA. Demographic and clinical features were retrieved from the medical charts. Multivariate binary logistic regression was used to determine the independent predictive factors for the occurrence of specific mutations, in the whole study population or in selected subgroups.
Findings: The overall respective incidence of EGFR, KRAS, BRAF, ERBB2 and PI3KCA mutations was 10.5%, 0.9%, 25%, 1.5%, 2.1% and 1.4%, in our study sample including 87.4% white Caucasians, 10.8% Africans and 1.8% Asians; 60.6% men, 30.7% never smoker (median age: 68.3 years). Ethnicity was an independent predictor for EGFR, KRAS and ERBB2 gene abnormalities. In all cases, a significantly higher prevalence of targetable EGFR and ERBB2, and a lower prevalence of resistance KRAS mutations were observed in African women as compared to African men or Caucasians.
Conclusions: In real life conditions of routine genetic testing, we have identified subsets of patients with specific targetable activating somatic mutations according to ethnicity, who could preferentially benefit from anti-EGFR and anti-ERBB2 targeted therapies.
| Item Type: | Journal Article |
|---|---|
| Subjects: | R Medicine > RC Internal medicine |
| Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Biomedical Sciences Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Biomedical Sciences > Translational & Experimental Medicine Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
| Library of Congress Subject Headings (LCSH): | Lungs -- Cancer -- Genetic aspects -- France, Adenocarcinoma, Ethnicity -- Health aspects -- France |
| Journal or Publication Title: | Oncotarget |
| Publisher: | Impact Journals LLC |
| ISSN: | 1949-2553 |
| Official Date: | 7 February 2017 |
| Dates: | Date Event 7 February 2017 Published 9 January 2017 Accepted |
| Volume: | 8 |
| Page Range: | pp. 50792-50803 |
| DOI: | 10.18632/oncotarget.15132 |
| Status: | Peer Reviewed |
| Publication Status: | Published |
| Access rights to Published version: | Open Access (Creative Commons open licence) |
| Date of first compliant deposit: | 30 June 2017 |
| Date of first compliant Open Access: | 4 July 2017 |
| URI: | https://wrap.warwick.ac.uk/89664/ |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |